Skip to main content

Metastatic Prostate Cancer

Oncology
28
Pipeline Programs
30
Companies
26
Clinical Trials
6 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
12
5
5
0
2
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
889%
Cell Therapy
111%
+ 29 programs with unclassified modality

Metastatic Prostate Cancer is a $3.7B market in peak maturity, dominated by two established androgen receptor antagonists with limited competitive diversity.

$3.7B marketMature→ Stable3 products3 companies

Key Trends

  • Androgen receptor antagonists command 100% of quantified revenue with XTANDI leading at 71% market share
  • Emerging radioligand therapy (PLUVICTO) represents first non-AR mechanism but lacks published spending data, signaling early adoption phase
  • High clinical trial activity (94 trials across all phases) indicates active pipeline development despite market consolidation

Career Verdict

This is a stable but consolidating market—ideal for commercial and clinical operations roles, but limited upside for those seeking emerging science exposure or significant market growth.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1XTANDIStable
$2.6B
Astellas·Peak10.7yr
#2ERLEADAStable
$1.1B
Johnson & Johnson·Peak13.7yr
#3PLUVICTOStable
Novartis·Peak15.3yr

Drug Class Breakdown

Androgen Receptor Antagonists
$2.6B(71%)

mature market leader

AR Inhibitors (Direct Ligand-Binding Domain)
$1.1B(29%)

established second-line option

Radioligand Therapy
(0%)

early-stage diversification

Career Outlook

Stable

Metastatic prostate cancer remains a high-revenue, stable market with robust hiring but limited growth trajectory. The shift toward radioligand and combination therapies creates pockets of innovation, but the market's reliance on two aging small molecules means career advancement will depend on clinical operations expertise and commercial execution rather than breakthrough science. Patent cliffs in 2037-2040 will drive consolidation and potential layoffs post-LOE.

Breaking In

Enter via Clinical Operations or Regulatory roles at J&J or Novartis to build oncology credentials; avoid this indication if seeking rapid career growth or cutting-edge science exposure.

For Experienced Professionals

Experienced oncology professionals should leverage the stable revenue base and strong hiring to negotiate premium compensation, but plan for portfolio diversification before 2037 patent cliffs reshape the market.

In-Demand Skills

Oncology clinical trial managementRadiopharmaceutical expertise (for PSMA-targeting agents)Global regulatory strategy for hormonal therapiesResistance mechanism and biomarker assessmentMarket access and reimbursement in mature oncology

Best For

Medical Science Liaison (high salaries, stable demand)Clinical Operations ManagerOncology Brand Manager (J&J, Novartis)Regulatory Affairs SpecialistHealth Economics & Outcomes Research

Hiring Landscape

$166K-$356K

Johnson & Johnson dominates hiring with 1,763 active positions, followed by Novartis with 599 positions. Commercial roles lead volume (414 jobs, $257K avg), but Clinical Operations offers the highest compensation ($356K avg) and reflects the capital-intensive nature of late-stage prostate cancer trials. Engineering and R&D positions reflect manufacturing and formulation challenges specific to radioligand and advanced AR agents.

2,362
Open Roles
2
Companies Hiring
3
Departments

Top Hiring Companies

Johnson & Johnson
1763Growing
Novartis
599Growing

By Department

Commercial(18%)
$257K
Clinical Operations(8%)
$356K
Engineering(8%)
$215K

Strong hiring velocity at J&J and Novartis indicates sustained market investment, with premium compensation in clinical and commercial roles offsetting lower pipeline excitement.

On Market (2)

Approved therapies currently available

Exelixis
CABOMETYXApproved
cabozantinib
Exelixis
oral2016
1.1B Part D
Exelixis
COMETRIQApproved
cabozantinib
Exelixis
oral2012
3M Part D

Competitive Landscape

27 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
1
1
EligardPhase 41 trial
PACE with CabazitaxelPhase 11 trial
Active Trials
NCT03110588Withdrawn0Est. Dec 2019
NCT01933022Terminated1Est. Aug 2015
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
Dexamethasone plus Radium-223Phase 41 trial
MitoxantronePhase 21 trial
Active Trials
NCT00452387Terminated22Est. Jan 2009
NCT03432949Unknown24Est. Jul 2024
Exelixis
ExelixisCA - Alameda
1 program
1
1
CabozantinibPhase 3Small Molecule
Telix Pharmaceuticals
Telix PharmaceuticalsAustralia - Brisbane
3 programs
2
1
177Lu-DOTA-rosopatambPhase 31 trial
177Lu-DOTA-TLX591Phase 11 trial
64Cu-DOTA-TLX592Phase 11 trial
Active Trials
NCT04786847Completed30Est. Sep 2023
NCT04726033Completed14Est. Jan 2024
NCT04876651Terminated16Est. Jul 2025
Biocorp
BiocorpFrance - Issoire
1 program
1
Active PPP005Phase 21 trial
Active Trials
NCT03763851Terminated100Est. Nov 2018
Alliance Pharmaceuticals
1 program
1
DarolutamidePhase 2
Pfizer
PfizerNEW YORK, NY
1 program
1
SunitinibPhase 2Small Molecule1 trial
Active Trials
NCT00599313Completed36Est. Jun 2009
Dendreon
DendreonCA - Seal Beach
1 program
1
sipuleucel-TPhase 2Cell Therapy1 trial
Active Trials
NCT01981122Completed52Est. Jun 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
3
AZD0516Phase 1/21 trial
AZD0754Phase 1/21 trial
AZD5305Phase 1/2
Active Trials
NCT07181161Recruiting177Est. Jan 2029
NCT06267729Recruiting60Est. Nov 2026
ImmunoGenesis
ImmunoGenesisTX - Houston
1 program
1
EvofosfamidePhase 1/21 trial
Active Trials
NCT06782555Recruiting71Est. Jan 2028
ImaginAb
ImaginAbCA - Inglewood
1 program
1
[89Zr]Df-IAB2MPhase 1/21 trial
Active Trials
NCT01923727Completed38Est. Jun 2016
Sandoz
SandozAustria - Kundl
3 programs
1
177Lu-PSMA-617Phase 11 trial
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide TetraxetanN/A1 trial
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)N/A1 trial
Active Trials
NCT07484269Not Yet Recruiting753Est. Jul 2031
NCT07290270Recruiting170Est. Aug 2029
NCT07145177Recruiting30Est. Oct 2030
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
[¹⁴C]OpevesostatPhase 1Small Molecule
STEREOTACTIC BODY RADIOTHERAPY to the prostate glandN/A1 trial
Active Trials
NCT02206724Withdrawn0Est. Apr 2018
Prevail Therapeutics
1 program
1
DarolutamidePhase 11 trial
Active Trials
NCT05617885Active Not Recruiting9Est. Jun 2026
ORIC Pharmaceuticals
1 program
1
ORIC-944Phase 11 trial
Active Trials
NCT05413421Recruiting250Est. Sep 2026
FutureChem
FutureChemKorea - Seoul
1 program
1
[18F]FLORPhase 11 trial
Active Trials
NCT04528199Terminated8Est. Apr 2023
Orion Pharma
Orion PharmaUK - Reading
1 program
1
[¹⁴C]OpevesostatPhase 1Small Molecule1 trial
Active Trials
NCT06566989Completed8Est. Oct 2024
Orion
OrionUK - Cambridge
1 program
1
[¹⁴C]OpevesostatPhase 1Small Molecule
MSD
MSDIreland - Ballydine
1 program
1
[¹⁴C]OpevesostatPhase 1Small Molecule
Medpace
MedpaceCINCINNATI, OH
1 program
1
lutetiumPhase 11 trial
Active Trials
NCT06516510Terminated17Est. Aug 2025
Novartis
NovartisBASEL, Switzerland
2 programs
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide TetraxetanN/A
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)N/A
Ipsen
IpsenChina - Tianjin
2 programs
TazemetostatPHASE_1_2Small Molecule1 trial
abiraterone acetatePHASE_31 trial
Active Trials
NCT04179864Terminated102Est. Nov 2024
NCT01957436Active Not Recruiting1,173Est. Dec 2032
Providence Therapeutics
1 program
Anti-OX40PHASE_11 trial
Active Trials
NCT01303705Completed13Est. Jul 2016
Sanofi
SanofiPARIS, France
1 program
PACE with CabazitaxelPHASE_1
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
[¹⁴C]OpevesostatPHASE_1Small Molecule
Blue Earth Therapeutics
1 program
lutetiumPHASE_1
Parexel
ParexelMA - Boston
1 program
AZD0516PHASE_1_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BayerDexamethasone plus Radium-223
AstellasEligard
Telix Pharmaceuticals177Lu-DOTA-rosopatamb
Ipsenabiraterone acetate
BiocorpActive PPP005
Dendreonsipuleucel-T
BayerMitoxantrone
PfizerSunitinib
AstraZenecaAZD0516
ImmunoGenesisEvofosfamide
AstraZenecaAZD0754
IpsenTazemetostat
ImaginAb[89Zr]Df-IAB2M
Sandoz177Lu-PSMA-617
Medpacelutetium

Showing 15 of 26 trials with date data

Clinical Trials (26)

Total enrollment: 3,174 patients across 26 trials

NCT03432949BayerDexamethasone plus Radium-223

Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

Start: Feb 2018Est. completion: Jul 202424 patients
Phase 4Unknown
NCT01933022AstellasEligard

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

Start: Aug 2014Est. completion: Aug 20151 patients
Phase 4Terminated
NCT04876651Telix Pharmaceuticals177Lu-DOTA-rosopatamb

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Start: Aug 2023Est. completion: Jul 202516 patients
Phase 3Terminated
NCT01957436Ipsenabiraterone acetate

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

Start: Nov 2013Est. completion: Dec 20321,173 patients
Phase 3Active Not Recruiting
NCT03763851BiocorpActive PPP005

Cannabis Oil and Radiation Therapy for the Management of Pain

Start: Mar 2018Est. completion: Nov 2018100 patients
Phase 2Terminated
NCT01981122Dendreonsipuleucel-T

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Start: Sep 2013Est. completion: Jun 201752 patients
Phase 2Completed
NCT00452387BayerMitoxantrone

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Start: May 2007Est. completion: Jan 200922 patients
Phase 2Terminated
NCT00599313PfizerSunitinib

Phase II Sunitinib Prog Met AIPC

Start: Mar 2007Est. completion: Jun 200936 patients
Phase 2Completed
NCT07181161AstraZenecaAZD0516

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Start: Oct 2025Est. completion: Jan 2029177 patients
Phase 1/2Recruiting
NCT06782555ImmunoGenesisEvofosfamide

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Start: Jan 2025Est. completion: Jan 202871 patients
Phase 1/2Recruiting
NCT06267729AstraZenecaAZD0754

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Start: Mar 2024Est. completion: Nov 202660 patients
Phase 1/2Recruiting
NCT04179864IpsenTazemetostat

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Start: Nov 2019Est. completion: Nov 2024102 patients
Phase 1/2Terminated
NCT01923727ImaginAb[89Zr]Df-IAB2M

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

Start: Aug 2013Est. completion: Jun 201638 patients
Phase 1/2Completed
NCT07145177Sandoz177Lu-PSMA-617

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Start: Mar 2026Est. completion: Oct 203030 patients
Phase 1Recruiting
NCT06516510Medpacelutetium

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Start: Oct 2024Est. completion: Aug 202517 patients
Phase 1Terminated
NCT06566989Orion Pharma[¹⁴C]Opevesostat

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Start: Sep 2024Est. completion: Oct 20248 patients
Phase 1Completed
NCT05617885Prevail TherapeuticsDarolutamide

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Start: Aug 2023Est. completion: Jun 20269 patients
Phase 1Active Not Recruiting
NCT05413421ORIC PharmaceuticalsORIC-944

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Start: Jun 2022Est. completion: Sep 2026250 patients
Phase 1Recruiting
NCT04786847Telix Pharmaceuticals177Lu-DOTA-TLX591

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Start: Jan 2022Est. completion: Sep 202330 patients
Phase 1Completed
NCT04726033Telix Pharmaceuticals64Cu-DOTA-TLX592

64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)

Start: Aug 2021Est. completion: Jan 202414 patients
Phase 1Completed
NCT04528199FutureChem[18F]FLOR

[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Start: Feb 2021Est. completion: Apr 20238 patients
Phase 1Terminated
NCT03110588AstellasPACE with Cabazitaxel

Phase I Trial of PACE for Metastatic Prostate Cancer

Start: May 2018Est. completion: Dec 20190
Phase 1Withdrawn
NCT01303705Providence TherapeuticsAnti-OX40

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Start: Oct 2010Est. completion: Jul 201613 patients
Phase 1Completed
NCT07484269SandozPULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

Start: Aug 2026Est. completion: Jul 2031753 patients
N/ANot Yet Recruiting
NCT07290270SandozReal-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Start: Feb 2026Est. completion: Aug 2029170 patients
N/ARecruiting
NCT02206724Sharp TherapeuticsSTEREOTACTIC BODY RADIOTHERAPY to the prostate gland

Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer

Start: Jul 2014Est. completion: Apr 20180
N/AWithdrawn

Related Jobs in Oncology

Senior Manager, Supply Chain

Parabilis MedicinesParabilis Medicines
Cambridge, MA
5d ago
$153K - $180K/yr

Senior Associate Scientist, Biology

Parabilis MedicinesParabilis Medicines
Cambridge, MA
5d ago
$88K - $108K/yr

Director, Intellectual Property

Parabilis MedicinesParabilis Medicines
Cambridge
1w ago
$220K - $290K/yr

Bioinformatics Research Scientist II

VeracyteVeracyte
Remote
1w ago
$122K - $166K/yr

Senior Oncology Account Specialist Prostate Cancer Las Vegas, NV

PfizerPfizer
Remote
1w ago
$109K - $251K/yr

Desktop Support Specialist

ArvinasArvinas
New Haven - CT
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 actively recruiting trials targeting 3,174 patients
30 companies competing in this space

Related Indications

Breast Cancer(1518)Non-small Cell Lung Cancer(976)Prostate Cancer(814)Multiple Myeloma(669)Cancer(668)Advanced Solid Tumors(522)Advanced Solid Tumor(465)Colorectal Cancer(464)Melanoma(462)Solid Tumor(434)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.